Abstract
Prostate cancer (PC) is a heterogeneous disease, with a complex natural history, whose growth is driven by androgens and androgen receptors. In most cases, patients have localized disease at presentation, which may be successfully treated with radical prostatectomy and external beam radiation. However, many patients subsequently develop metastatic disease. De novo metastases can also occur in a minority of cases.Androgen deprivation therapy (ADT) is the standard treatment of metastatic hormone-naïve (or castration-sensitive) prostatic cancer (CSPC). ADT usually determines a profound PSA decline and a radiological and clinical benefit in most patients. However, essentially all patients experience progression to castration-resistant prostate cancer (CRPC) despite persisting low testosterone levels in around 1–2 years, and overall prognosis remains disappointing, although subsequent active treatments are available. Early targeting of cells that survive hormonal therapy may potentially prevent the development of CRPC. The aim of these therapeutic strategies is the elimination of resistant cells at the time the tumor is apparently “androgen sensitive”. The large randomized studies analyzed in this chapter, addressing the early use of docetaxel in combination with ADT in men with metastatic CSPC, have shown evidence that at least a subset of patients with metastatic CSPC may benefit from the combination of ADT with docetaxel as initial therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016.CA. Cancer J Clin 66:7–30
Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357
Attard G, Parker C, Eeles RA et al (2016) Prostate cancer. Lancet 387:70–82
Wu JN, Fish KM, Evans CP et al (2014) No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 120:818–823
Miller DC, Hazer KS, Stewart A et al (2003) Prostate carcinoma presentation, diagnosis and staging: an update from the National Cancer Data Base. Cancer 98:1169–1178
Ryan CJ, Elkin EP, Small EJ et al (2006) Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 24:396–402
Center MM, Jemal A, Lortet-Tieulent J et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079–1092
Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213
Wallis CJ, Saskin R, Choo R et al (2015) Surgery versus radiotherapy for clinically localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70(1):21–30
Huggins C, Hodges CV (1941) Studies in prostate cancer. 1. The effect of castration of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297
Gillessen S, Omlin A, Attard G et al (2016) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:1589–1604
D’Angelillo RM, Franco P, De Bari B et al (2015) Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. Crit Rev Oncol Hematol 93:136–148
Hussain M, Tangen C, Higano C et al (2016) Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details. J Clin Oncol 34:180–185
Magnan S, Zarychanski R, Pilote L et al (2015) Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol 1:1261–1269
Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491–1498
Samson DJ, Seidenfeld J, Schmitt B et al (2002) Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95:361–376
James ND, Spears MR, Clark NW et al (2015) Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67:1028–1038
Zong Y, Goldstein AS (2013) Adaptation or selection: mechanisms of castration-resistant prostate cancer. Nat Rev Urol 10:90–98
Ahmed M, Li LC (2013) Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 20:362–371
Goldstein AS, Stoyanova T, Witte ON (2010) Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol 4:385–396
Eigl BJ, Eggener SE, Baybik J et al (2005) Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 11:4905–4911
Tang Y, Khan MA, Goloubeva O et al (2006) Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 12:169–174
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
Zhu ML, Horbinski CM, Garzotto M et al (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992–8002
De Reijke TM, Keuppens FL, Whelan P et al (1999) Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patient with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol 162:1658–1664
Janknegt RA, Boon TA, van de Beek C, Grob P (1997) Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 49:411–420
Noguchi M, Noda S, Yoshida M et al (2004) Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103–109
Millikan RE, Wen S, Pagliaro LC et al (2008) Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26:5936–5942
Pummer K, Lehnert M, Stettner H, Hubmer G (1997) Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81–85
Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149–158
Gravis G, Boher J-M, Joly F et al (2016) Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: long-term analysis of the GETUG-AFU-15 phase III trial. Eur Urol 70(1):21–30
Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746
James ND, Sydes MR, Clarke NW et al (2008) STAMPEDE: systemic therapy for advancing or metastatic prostate cancer. A Multi-arm multi-Stage randomised controlled trial. Clin Oncol 20:577–581
James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomized controlled trial. Lancet 387:1163–1177
Glass TR, Tangen CM, Crawford ED, Thompson I (2003) Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 169:164–169
James ND, Sydes MR, Mason MD et al (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomized controlled trial. Lancet Oncol 13:549–558
Sydes MR, Parmar MK, Mason MD et al (2012) Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13:168
Attard G, Sydes MR, Mason MD et al (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 66:799–802
Tucci M, Bertaglia V, Vignani F et al (2016) Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol 69:563–573
Vale CL, Burdett S, Rydzewska LHM et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localized or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:243–256
Fizazi K, Faivre L, Lesaunier F et al (2015) Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localized prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 16:787–794
Halabi S, Lin CY, Kelly WK et al (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32:671–677
Halabi S, Kelly WK, Ma H et al (2016) Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34:1652–1659
Gravis G, Boher JM, Fizazi K et al (2015) Prognostic factors for survival in non-castrate metastatic prostate cancer: validation of the Glass model and development of a novel simplified prognostic model. Eur Urol 68:196–204
Fizazi K, Jenkins C, Tannock IF (2015) Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol 26:1660–1667
Franke RM, Carducci MA, Rudek MA, et al (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562–4567
Templeton AJ, Vera-Badillo FE, Wang L, et al (2013) Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 24:2972–2977
Fizazi K, Abrahamsson P-A, Ahlgren G, et al (2015) Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 67:904–912
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ceresoli, G.L., Bonomi, M., Sauta, M.G., Zanardi, E., Boccardo, F. (2017). Combinations of Hormonal Therapy and Chemotherapy. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-42327-2_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42326-5
Online ISBN: 978-3-319-42327-2
eBook Packages: MedicineMedicine (R0)